Sensyne Health to collaborate with Bayer on patient data capability

Sensyne Health and Bayer are to collaborate on developing a national linked patient data capability to accelerate new medicine discovery and development. Bayer will bring the relevant pharmaceutical R&D expertise and capability to the current consortium of Sensyne Health, EY, JP Morgan, Microsoft and Peel Hunt who have the clinical AI, computing, investment banking, data analytics, systems integration and business planning skills required. Together they will develop proposals to scale Sensyne Health’s current network of strategic research agreements with NHS Trusts to improve patient care through the analysis of large databases of anonymised patient data. The NHS will remain the controller of NHS patient data, and no data will be sold or transferred to a third party.
Kemal Malik, Bayer board member for Innovation, said: “Access to anonymised national linked patient data heralds a new era in the discovery and development of medicines. Through the application of artificial intelligence to large sets of patient information it becomes possible to identify people that are most likely to be at risk of diseases in the future. Importantly, this will allow steps to prevent their progress along that path. Bayer is excited to make its expertise available to develop this capability.”